Biodiesel commercialization is questionable due to poor brake thermal efficiency. Biodiesel utilization should be improved with the addition of fuel additives. Hydrogen peroxide is a potential fuel additive due to extra hydrogen and oxygen content, which improves the combustion process. In this experimental study, biodiesel has been produced from Jatropha oil employing catalyzed transesterification homogeneously to examine its influence on the performance and emissions at engine loads with 1500 rpm utilizing a four-stroke single-cylinder diesel engine. D60B40 (having 60% diesel and 40% biodiesel) and D60B30A10 (60% diesel, 30% biodiesel and 10% hydrogen peroxide (H2O2)), are the fuel mixtures in the current study. The addition of H2O2 reduces emissions and enhances the combustion process. This effect occurred due to the micro-explosion of the injected fuel particles (which increases in-cylinder pressure and heat release rate (HRR)). An increase of 20% in BTE and 25% reduction in BSFC for D60B30A10 was observed compared to D60B40. Significant reduction in emissions of HC up to 17.54%, smoke by 24.6% CO2 by 3.53%, and an increase in NOx was noticed when the engine is operated with D60B30A10. The HRR increased up to 18.6%, ID reduced by 10.82%, and in-cylinder pressure increased by 8.5%. Test runs can be minimized as per Taguchi's design of experiments. It is possible to provide the estimates for the full factorial design of experiments. Exhaust gas temperature standards are evaluated and examined for all fuel blends.
A novel and potent series of ene-amides featuring azetidines has been developed as FabI inhibitors active against drug resistant Gram-positive pathogens particularly staphylococcal organisms. Most of the compounds from the series possessed excellent biochemical inhibition of Staphylococcus aureus FabI enzyme and whole cell activity against clinically relevant MRSA, MSSA and MRSE organisms which are responsible for significant morbidity and mortality in community as well as hospital settings. The binding mode of one of the leads, AEA16, in Escherichia coli FabI enzyme was determined unambiguously using X-ray crystallography. The lead compounds displayed good metabolic stability in mice liver microsomes and pharmacokinetic profile in mice. The in vivo efficacy of lead AEA16 has been demonstrated in a lethal murine systemic infection model.